

SIGNET



Reducing complexity in clinical diagnosis and treatment pathways

Project summary

The aim of SIGNET is to realize the North Star of replacing complex medical workflows and procedures by single-episode personalized, dose-adaptive, precision Magnetic Resonance guided treatments and interventions, improving patient comfort, safety, treatment outcome, and economic viability.

Winner ITEA Award for Exceptional Excellence 2025



Project duration

November 2021 - January 2025

Expected key results / USPs

- Single unified interface for the treatment device manufacturers to integrate with the MR system across neurology, cardiology & oncology domains.
- > Better Al driven image quality with up to 60% faster speed.
- > SIGNET innovations will position European MR guided treatment industry to more effectively compete with the ventures from the rest of the world, and allow treatment device manufacturers a quicker path to clinical evaluation and market adoption.
- Expected direct annual societal gain of over EUR 1 billion by the end of this decade, through these innovations.

Project website Project LinkedIn








https://www.linkedin.com/company/itea-signet/

SIGNET technology building blocks





Contact

Saurav Kumar Baidya Philips - The Netherlands E: saurav.baidya@philips.com T: +31 6 3809 9296 This ITEA project is supported by:



